Contributions
Abstract: PB2309
Type: Publication Only
Background
Thrombotic events are considered a major complication in the follow-up, and treatment of Philadelphia negative Myeloproliferative Neoplasms (MPN), particularly polycythemia vera and essential thrombocythemia, associated with high morbidity and mortality, as reported in several retrospective studies.
Aims
To study the incidence of thrombotic events at diagnosis and during follow up of Egyptian MPN patients
Methods
We studied 102 adult Egyptian patients diagnosed with Ph (-) ve MPN (M/F 49/53, mean age 50.13 ±12.1 years), at Mansoura Oncology center during the period from May 2012 till December 2017. Of them 47(46.1%) had Polycythemia Vera(PV), 27(26.5%) Essential Thrombocytosis(ET),22(21.6%) Myelofibrosis(MF), and 6(5.9%) Unclassified.
Results
Out of the 102 patient observed during the period of the study 32(31.45) patients was having thrombotic episodes, out of these 26 (25.5%) at diagnosis, 6 (5.9%) patient at follow up and 4 (3.9%) is said to have recurrent thrombotic events. These thrombotic events were 15 arterial (6 cereberal.3 lower limb, 2 upper limbs. 2 hepatic, and I coronary), 13 venous (7 portal, 4splenis, and 2 lower limbs), and 4 patients were having combined arterio-venous thrombosis. As to the incidence of early thrombosis in the different MPNs, they were 14/47 (29.8%) in PV patients,8/27 (29.6%) in ET patients and 7/22 (31.8%) in PMF patients and 3/6(50%) unclassified patients. The median time from diagnosis to thrombotic event was also similar in the different MPNs (p=0.311). Several clinical features at diagnosis (age, gender, Hb levels, WBC and PLT counts, JAK-2 V617F mutation and previous thrombotic events) were evaluated for a role in predicting thrombotic events: only age and previous thrombotic events were significant. The overall survival was affected significantly with the presence of thrombosis (P = 0.097), while the JAKII V617F positivity has no survival affection
Conclusion
The incidence of early and recurrent thrombosis seems to be without any difference among ET, PV and PMF. Only age and previous thrombotic events had a predictive role, affecting the overall survival.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Myeloproliferative disorder, Thrombosis
Abstract: PB2309
Type: Publication Only
Background
Thrombotic events are considered a major complication in the follow-up, and treatment of Philadelphia negative Myeloproliferative Neoplasms (MPN), particularly polycythemia vera and essential thrombocythemia, associated with high morbidity and mortality, as reported in several retrospective studies.
Aims
To study the incidence of thrombotic events at diagnosis and during follow up of Egyptian MPN patients
Methods
We studied 102 adult Egyptian patients diagnosed with Ph (-) ve MPN (M/F 49/53, mean age 50.13 ±12.1 years), at Mansoura Oncology center during the period from May 2012 till December 2017. Of them 47(46.1%) had Polycythemia Vera(PV), 27(26.5%) Essential Thrombocytosis(ET),22(21.6%) Myelofibrosis(MF), and 6(5.9%) Unclassified.
Results
Out of the 102 patient observed during the period of the study 32(31.45) patients was having thrombotic episodes, out of these 26 (25.5%) at diagnosis, 6 (5.9%) patient at follow up and 4 (3.9%) is said to have recurrent thrombotic events. These thrombotic events were 15 arterial (6 cereberal.3 lower limb, 2 upper limbs. 2 hepatic, and I coronary), 13 venous (7 portal, 4splenis, and 2 lower limbs), and 4 patients were having combined arterio-venous thrombosis. As to the incidence of early thrombosis in the different MPNs, they were 14/47 (29.8%) in PV patients,8/27 (29.6%) in ET patients and 7/22 (31.8%) in PMF patients and 3/6(50%) unclassified patients. The median time from diagnosis to thrombotic event was also similar in the different MPNs (p=0.311). Several clinical features at diagnosis (age, gender, Hb levels, WBC and PLT counts, JAK-2 V617F mutation and previous thrombotic events) were evaluated for a role in predicting thrombotic events: only age and previous thrombotic events were significant. The overall survival was affected significantly with the presence of thrombosis (P = 0.097), while the JAKII V617F positivity has no survival affection
Conclusion
The incidence of early and recurrent thrombosis seems to be without any difference among ET, PV and PMF. Only age and previous thrombotic events had a predictive role, affecting the overall survival.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Myeloproliferative disorder, Thrombosis